Retapamulin
FDA-approved product (ointment, topical), marketed as Altabax.
- Registered studies
- 19
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Impetigo
- Staphylococcal skin infections
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antibiotics for topical use
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC D06AX13
Repurposing investigation
Retapamulin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae39.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis43.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
19registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Retapamulin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pipecuronium BromideExisting use: Other quaternary ammonium compounds42.9% AI-predicted activityagainst K. pneumoniae5 registered studies
- Fosaprepitant DimeglumineExisting use: Cancer, Chemotherapy-induced nausea and vomiting, Nausea and 3 more42.9% AI-predicted activityagainst K. pneumoniae21 registered studies
- CabergolineExisting use: Hypothalamic neoplasm, Parkinson disease42.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more42.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder42.6% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Vecuronium BromideExisting use: Other quaternary ammonium compounds42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease42.0% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia41.9% AI-predicted activityagainst K. pneumoniae6 registered studies
- RepotrectinibExisting use: Cancer, Neoplasm41.8% AI-predicted activityagainst K. pneumoniae17 registered studies
- MoxidectinExisting use: Helminthiasis, Onchocerciasis41.7% AI-predicted activityagainst K. pneumoniae25 registered studies
- PralsetinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 1 more41.5% AI-predicted activityagainst K. pneumoniae19 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
NCT00539994 · start 2007-09
Registered record
- Registry ID
- NCT00539994
- Conditions
- Infections, Bacterial
- Interventions
- retapamulin; Retapamulin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-09
- Completion
- 2008-01
- Enrolment
- 57
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfections, BacterialInterventionretapamulin; Retapamulin; PlaceboPhasePhase 2Registry statusCompletedPharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
NCT00555061 · start 2007-09
Registered record
- Registry ID
- NCT00555061
- Conditions
- Skin Infections, Bacterial
- Interventions
- Retapamulin Ointment, 1%
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2007-09
- Completion
- 2008-08
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSkin Infections, BacterialInterventionRetapamulin Ointment, 1%PhasePhase 4Registry statusCompletedTreatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
NCT00133848 · start 2005-04
Registered record
- Registry ID
- NCT00133848
- Conditions
- Impetigo
- Interventions
- SB-275833 ointment, 1%
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-04
- Completion
- 2006-01
- Enrolment
- 210
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImpetigoInterventionSB-275833 ointment, 1%PhasePhase 3Registry statusCompletedTopical SB-275833 Ointment, 1% For The Treatment Of Impetigo
NCT00133874 · start 2005-04
Registered record
- Registry ID
- NCT00133874
- Conditions
- Skin Infections, Bacterial
- Interventions
- SB-275833 ointment, 1%
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-04
- Completion
- 2005-09
- Enrolment
- 520
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSkin Infections, BacterialInterventionSB-275833 ointment, 1%PhasePhase 3Registry statusCompleted